文献速递膀胱癌与上尿路尿路上皮癌前列腺癌

前列腺癌盆腔放疗后机器人辅助膀胱切除加体内尿流改道:技术及单中心结果

Robot-assisted Cystectomy with Intracorporeal Urinary Diversion After Pelvic Irradiation for Prostate Cancer: Technique and Results from a Single High-volume Center.
PubMed 文献 · Eur Urol · 2021-04-08

本研究回顾性评估32例因前列腺癌放疗后晚期泌尿不良事件行机器人辅助膀胱切除联合体内尿流改道的患者,中位年龄校正Charlson合并症指数为6,主要适应症为出血性放射性膀胱炎(91%)。中位失血量250ml、手术时间330min、住院10天,90天内Clavien-Dindo≥IIIa级并发症率为28%,晚期并发症率46%,围手术期死亡率为0%。单因素分析显示年龄校正Charlson合并症指数是早期并发症的唯一相关因素(OR 1.75,95%CI 1.05-2.9;p=0.03)。

要点

  • 放疗后晚期泌尿不良事件行机器人辅助膀胱切除联合体内尿流改道在高流量中心可行。
  • 90天内Clavien-Dindo≥IIIa级并发症率为28%,晚期并发症率为46%,围手术期死亡率为0%。
  • 年龄校正Charlson合并症指数与早期并发症风险相关(OR 1.75,95%CI 1.05-2.9;p=0.03)。

核心结论

  • 对于有盆腔放疗史的前列腺癌患者,机器人辅助膀胱切除联合体内尿流改道治疗晚期泌尿不良事件在高流量中心是可行选择。

研究设计与样本

  • 单中心回顾性研究,纳入32例因放疗后泌尿不良事件行机器人辅助膀胱切除联合体内尿流改道的患者。
  • 手术使用da Vinci Xi系统,并根据主要治疗进行调整。

主要发现

  • 中位年龄校正Charlson合并症指数为6(IQR 5-7)。
  • 适应症为出血性放射性膀胱炎29例(91%)、挛缩膀胱2例(6.2%)、尿瘘1例(3.1%)。
  • 中位失血量250ml、手术时间330min、住院时间10天。
  • 31例(97%)患者接受回肠导管。
  • 90天内Clavien-Dindo≥IIIa级并发症率为28%,晚期并发症率为46%,围手术期死亡率为0%。

临床怎么用

  • 对于前列腺癌放疗后出现出血性放射性膀胱炎、挛缩膀胱或尿瘘等晚期泌尿不良事件的患者,可考虑在高流量中心行机器人辅助膀胱切除联合体内尿流改道。
  • 术前应评估年龄校正Charlson合并症指数,其与早期并发症风险相关。

局限性

  • 缺乏与开放膀胱切除术的比较是主要局限性。
  • 回顾性单中心设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radiation therapy (RT) for prostate cancer (PCa) treatment is burdened by high rates of late urinary adverse events (UAEs). The feasibility of robot-assisted cystectomy (RAC) with intracorporeal urinary diversion (ICUD) for treatment of high-grade UAEs has never been assessed. OBJECTIVE: To report perioperative outcomes, early (≤90 d) and late (>90 d) complications among patients undergoing RAC for UAEs after RT. DESIGN, SETTING, AND PARTICIPANTS: We retrospectively evaluated 32 patients undergoing RAC with ICUD for UAEs in a single tertiary centre. SURGICAL PROCEDURE: Surgery was performed using a da Vinci Xi system with adaptation for the primary treatment. MEASUREMENTS: Perioperative outcomes included estimated blood loss (EBL), operative time (OT), intraoperative complications, and length of stay (LOS). Data for early and late postoperative complications were collected using the quality criteria recommended by the European Association of Urology. Univariate logistic regressions were performed to test the effect of baseline and perioperative characteristics on early postoperative complications. RESULTS AND LIMITATIONS: The median age-adjusted Charlson comorbidity index (ACCI) was 6 (IQR 5-7). The indication for RAC was hemorrhagic radiation cystitis in 29 cases (91%), contracted bladder in two cases (6.2%), and urinary fistula in one case (3.1%). The median EBL, OT, and LOS were 250 ml, 330 min, and 10 d, respectively. A total of 31 (97%) patients received an ileal conduit. The 90-d rate of Clavien-Dindo grade ≥IIIa complications was 28%. The late complication rate was 46% and the perioperative mortality rate was 0%. On univariate analyses, ACCI was the only parameter correlated with the risk of early complications (odds ratio 1.75, 95% confidence interval 1.05-2.9; p = 0.03). The median follow-up was 30 mo (IQR 15-40). The lack of comparison with open cystectomy represents the main limitation. CONCLUSIONS: RAC for UAEs in patients with a history of pelvic irradiation is a feasible option in high-volume centers. The use of new technologies can help to overcome some of the technical difficulties and reduce the risk of perioperative and late complications. PATIENT SUMMARY: We report our experience with robot-assisted surgery for removal of the bladder in the management of urinary problems after radiation therapy for prostate cancer. When performed by highly experienced surgeons, this is a feasible procedure with outcomes and early and late complication rates that are acceptable.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Piazza P, Rosiello G, Chacon VT, et al. Robot-assisted Cystectomy with Intracorporeal Urinary Diversion After Pelvic Irradiation for Prostate Cancer: Technique and Results from a Single High-volume Center. Eur Urol. 2021. PMID: 33838960. doi:10.1016/j.eururo.2021.03.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。